Select Page
Event info
Date:17 Jan
Time:8:30-11:00
Venue:Medicon Valley Alliance Copenhagen

SIGN UP

Contact person
Jannie Rask de Vitt

Jannie Rask de Vitt

Network & Event Assistant

jrv@mva.org

+45 2629 2989

Selection of CDMO for your Project – When, Who and How?

All projects are different, but a number of parameters are consistent in addition to the guidelines/requirements from ICH, FDA, EMA. Selected characteristics of Small Molecule development projects will be discussed.

Highlighting topics concerning:

  • Management of risk and investment
  • Optimization and adaptation of MedChem procedures towards manufacturing
  • Sustainability
  • Introduction of green(-er) chemistry
  • Cost of waste management
  • Selection and sourcing of raw materials
  • Risk balancing of time versus cost
  • Delivery stages, hard and soft deadlines
  • Staging of the overall development-costs

When should each activity be initiated?
How to manage this?

Date: Wednesday 17th of January 2024
Time: 8:30 – 11:00
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Denmark – Meeting room: Auditorium

SIGN UP

Program

08:30 Networking, registration, and light breakfast 
09:00 Welcome
David Munis Zepernick, Director, Member Engagement & Communication, Medicon Valley Alliance
09:05 Company Introduction, Raybow
Peter Halkjær-Knudsen, CEO of Raybow Europe, Head of Mergers and Acquisitions, Jiuzhou Pharmaceuticals
09:20 Selection of CDMO for your Project – When, Who and How? How to secure a smooth and efficient transfer of a small molecule from Research to Market
Peter Halkjær-Knudsen, CEO of Raybow Europe, Head of Mergers and Acquisitions, Jiuzhou Pharmaceuticals
10:00 Q&A session 
10:15 Networking 
11:00 End of Good Morning Meeting

 

Speaker​​​

 
Peter Halkjær-Knudsen, CEO of Raybow Europe, Head of Mergers and Acquisitions, Jiuzhou Pharmaceuticals
A veteran of over 25 years in discovery and development.
Peter graduated as organic chemist from University of Copenhagen and has been working most of his career inside corporations in USA, Switzerland, Sweden and China.
He brings a deep understanding of the chemical development taking place from a target compound is identified to the point of filing an NDA.
Lately Peter has also been engaged in establishing solutions for secure sourcing and on-time manufacturing & delivery.
 

 

Organized by In collaboration with